What does half-life mean in PRRT?
In peptide receptor radionuclide therapy (PRRT), half-life describes a decrease over time, but the measurement must be named. Physical half-life concerns radioactive decay. Biological half-life concerns removal from the body or a specified compartment, considered separately from radioactive decay. Effective half-life combines those processes for the compartment and model being studied.
The IAEA radiopharmaceutical guidance distinguishes physical decay, biological clearance and uptake when describing time–activity curves. That distinction makes a statement such as “the PRRT half-life is six days” incomplete: which radionuclide, which process and which tissue does it describe?
Scroll horizontally to read all columns.
| Term | What changes? | What must be specified? |
|---|---|---|
| Physical half-life | Activity decreases through radioactive decay. | The radionuclide. |
| Biological half-life | Material leaves the compartment through biological processes. | The compound, compartment and kinetic model. |
| Effective half-life | Activity decreases through decay and biological removal together. | The tissue or compartment, measurement and model. |
What is the physical half-life of lutetium-177?
The LUTATHERA prescribing information lists a physical half-life of 6.647 days for lutetium-177, approximately 6.65 days. This is a property of the radionuclide; it is not a universal clearance time for a radiopharmaceutical in every organ.
Considering physical decay alone, half the starting activity remains after one physical half-life and one quarter remains after two. “One half-life” therefore does not mean “no radioactivity remains.” Biological removal can change the activity measured in a particular tissue as well.
How do biological and effective half-life differ?
A biological half-life describes removal from the compartment being investigated. Blood, a kidney, a tumor and the whole body are different measurement contexts. Material leaving one compartment need not have left the whole body. The EANM dosimetry recommendations discuss tissue-specific time–activity measurements rather than a single interchangeable number.
The simple effective half-life relationship
For a single exponential clearance phase with constant, independent rates of radioactive decay and biological removal, the relationship is:
1 / T_effective = 1 / T_physical + 1 / T_biological
Equivalently, T_effective = (T_physical × T_biological) / (T_physical + T_biological). Use the same time unit throughout. The product-over-sum relationship appears in the IAEA guidance; the reciprocal form expresses the same arithmetic.
Under these assumptions, adding biological removal makes the effective half-life shorter than either finite component half-life. If biological removal is negligible, the decline approaches physical decay alone. Continued uptake or several clearance phases requires a model that represents those processes; inserting a generic biological number does not establish a tissue's measured behavior.
Why is there no single effective half-life for every PRRT study?
The isotope's physical half-life does not identify a radiopharmaceutical's entire time–activity curve. The EANM recommendations distinguish measurements and fitting for organs and tumors. A reported effective half-life needs its tissue, acquisition method and model alongside it.
A 2025 clinical dosimetry study of Lu-177 DOTATATE reported a longer kidney effective half-life in its lower-kidney-function group than in its higher-function group. In that study, effective half-life was relatively stable across cycles for tumors and kidneys. These are findings from a defined study, not a universal clearance estimate for every patient or lesion.
When comparing two papers, first check whether both report the same compartment and the same kind of half-life. Our guide to reading peptide research provides a broader framework for matching a claim to its measurement.
What do the peptide and radionuclide each contribute?
PRRT uses a receptor-targeting radiopharmaceutical. In lutetium Lu 177 dotatate, receptor binding and the radionuclide have different roles. The product information describes highest binding affinity for somatostatin receptor subtype 2, followed by internalization; lutetium-177's beta emission contributes radiation-related cellular damage.
Related targeting biology does not make imaging and therapy the same intervention. The NETSPOT label describes gallium-68 dotatate as a PET diagnostic agent. A diagnostic scan records localization and uptake; it does not directly measure a later treatment response. The octreotide and lanreotide guide supplies additional somatostatin-family context.
Does half-life tell you how long PRRT works?
A decay or clearance measurement is not a duration-of-benefit measurement. The NETTER-1 randomized trial evaluated a Lu-177 dotatate treatment strategy in a selected population with progressive, somatostatin-receptor-positive midgut neuroendocrine tumors. Its progression-related outcomes answer a clinical question, rather than a question about radioactive decay.
Response, progression, survival and absorbed radiation dose are different outcomes. Our clinical endpoint guide explains why one result should not be renamed another. A half-life value alone cannot establish cure, predict an individual's response or set a universal radiation-safety timetable.
A checklist for reading a PRRT half-life claim
- Name the measurement: physical, biological or effective half-life.
- Identify the system: radionuclide, labeled compound and measured tissue or compartment.
- Read the model: uptake, clearance phase and fitting assumptions.
- Check the units: hours and days must be converted before comparing or combining values.
- Keep the endpoint separate: a time–activity result is not automatically a clinical benefit or safety conclusion.
For a different use of the term, compare the elimination-half-life discussion in the liraglutide peptide profile. The peptide classification guide places receptor-targeting constructs alongside other peptide roles.
